explore -WSS

explore

author：Wikipedia 2025-08-12 09:09:01 - browse：66

Adam's take main illustration — Molly Ferguson/STAT

Cytokinetics was founded 26 years ago but has not yet developed a drug successfully to approval. That makes Tuesday’s Food and Drug Administration decision on its treatment for heart failure a big deal — except nearly everyone, even investors who own Cytokinetics — hopes the agency rules against it.

Hoping the FDA rejects the Cytokinetics drug, called omecamtiv mecarbil, is a relatively uncommon, up-is-down, down-is-up situation, but it makes sense in this case because the business and science of the drug are not aligned.

Consider: Cytokinetics shares rose in December when an outside group of experts convened by the FDA to examine omecamtiv’s benefits and risks recommended against the medicine’s approval. On Tuesday, the FDA is most likely to heed that advice and turn down the company’s marketing application.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Chemotherapy drug shortage eases slightly but still widespread

explore

hotspot

WSS

Obesity drug from Roche shows promise in early study

HHS suspends federal funding for EcoHealth Alliance

Colorectal cancer study finds potential in overlooked immune cell

The future of health care in the House

Galapagos to make CAR

3 questions for the future of Biden's cancer moonshot

knowledge

explore

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

ChatGPT in medicine: STAT answers readers' burning questions

Analysis of telehealth claims data suggest service duplication

Virginia high school admissions case could be legal follow

Galapagos to make CAR

After affirmative action ruling, medical educators look to 'holistic review'

CVS is willing to dump 10% of its Medicare Advantage members

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Was Amgen transparent enough on FDA's concern on cancer drug?

hotspot

CVS is willing to dump 10% of its Medicare Advantage members

Liquid biopsy for lung cancer is launched by Delfi

Cherokee Nation medical school graduates its first class

A virus, fished out of a lake, may have saved a man’s life

ALS treatment from Biogen, Ionis fails in study

A Q&A with the global head of Boehringer Ingelheim's innovation unit

explore

entertainment

hotspot

focus